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Background: To correlate CD44/CD24 expression with gastric cancer recurrence and prognosis. Gastric cancer is
the second leading cause of cancer mortality due to the high recurrence rate, of which the molecular signature has
not yet been identified.
Methods: We retrospectively reviewed the hospital records of patients with gastric cancer. Among 500 patients
receiving curative resection, 95 patients had recurrence. Twenty patients from the recurrence group (95 patients)
and 20 patients from the non-recurrence group (405 patients) were randomly selected and identified as “study” and
“control” groups, respectively. We reviewed patients’ histological study of CD44/CD24 expression by performing
immunohistochemistry and recurrence rate.
Results: Study group had higher TNM stage (III-IV) than control group (80% vs. 25%, P= 0.001). Proportion of lymph
node metastasis was significantly higher in study group than that in control group (90% vs. 45%, P= 0.002), and
proportion of patients with 5 or more metastatic lymph nodes was also significantly higher in study group than in
control group (45% vs. 15%, P= 0.007). Univariate analysis revealed no difference in risk of gastric cancer recurrence
between CD44+ and CD44- patients (OR = 1.00, 95% CI: 0.29-3.45, P =1.000). CD24+ patients showed no greater
significance of gastric cancer recurrence than CD24- patients (OR = 1.86, 95% CI: 0.52-6.61, P= 0.339). After adjusting
for other risk factors, the association of CD44 expression (aOR = 0.66, 95% CI: 0.10-4.26, P= 0.658), CD24 expression
(aOR = 0.09, 95% CI: 0.01-1.35, P= 0.081) or combined (CD44/CD24) with gastric cancer recurrence were not
significant.
Conclusion: Neither individual expression of CD24 or CD44, nor combined expression of CD44/CD24 was
associated with recurrence of gastric carcinoma.
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Gastric cancer (GC) is the fifth leading cause of cancer
death in Taiwan, although its incidence and mortality
rate have been declining in the past five decades. Glo-
bally, GC is fourth most common among all types of
cancer diagnoses, and is the second leading cause of
cancer mortality [1], despite improvements in surgical
techniques and development of new chemotherapeutic
regimens. Annual deaths have reached 700,000 world-
wide and 42% are reported in China alone [1]. Even after* Correspondence: jimmyouyang@hotmail.com
1Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, No.95,
Wen Chang Road, Shih Lin District, Taipei City 11120, Taiwan
Full list of author information is available at the end of the article
© 2012 Yong et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcurative resection, 40% of patients with advanced gastric
cancer die of recurrence [2]. The prognosis for patients
after curative surgery remains poor due to the high re-
currence rate. The overall 5-year survival rate for
patients who undergo curative surgical resection for gas-
tric carcinoma ranges from 47% to 60.4%, and the recur-
rence rate ranges from 15.4% to 37% [3].
Genetic susceptibility variants and molecular altera-
tions related to environmental and lifestyle factors are
known to contribute to development of GC, but even
though many studies have investigated molecular mar-
kers for the disease, the true mechanisms of GC carcino-
genesis remain obscure [3]. Recurrence mechanisms also
lack definitive explanation [4]. Even though we knowtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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section, no molecular biomarker is currently available to
predict gastric carcinoma recurrence after resection.
While clinical predictive factors, such as tumor staging,
can predict recurrence of advanced gastric cancer and
are well recognized as essential predictors of prognosis,
is there any molecular-based biomarker that can serve as
a useful predictor for recurrence of advanced gastric
cancer after curative resection (R0 resection)?
Both CD44 and CD24 are known to contribute to cel-
lular signaling and cell adhesion, and their role in can-
cer recurrence has been investigated. In a review of
existing literature on the role of CD44/CD24 in recur-
rent human cancer, investigators showed positive asso-
ciations between CD44+/CD24- and prognosis,
especially in breast cancer; and the CD44+/CD24-
phenotype of breast cancer cells was also associated
with invasive properties. [5] CD44 and CD24 have been
shown to regulate invasion and metastasis of breast
cancer cells either positively or negatively. Tumorigenic
breast cancer cells that express high levels of CD44 and
low or undetectable levels of CD24 (CD44+/CD24-/low)
may be resistant to chemotherapy and therefore respon-
sible for cancer relapse [6]. CD44 was also highly
expressed in gastric adenocarcinoma and its expression
correlated with poor prognosis in patients with the in-
testinal type of gastric adenocarcinoma [7]. Based on
the implications of these previous studies, we hypothe-
sized that CD44+/CD24- expression might be corre-
lated with gastric cancer recurrence.
To our knowledge, current studies report no valid
adhesion molecule to predict disease recurrence after
patients undergo curative resection for gastric carcin-
oma. Because the significance of CD44+/CD24- is
probably not unique to breast cancer, and CD44 has
been highly expressed in gastric cancer, we might
speculate that similar or other molecules may also
regulate the process of recurrence for gastric cancer.
Therefore, we decided to investigate the expression of
adhesion molecule CD44/CD24 in recurrent gastric
cancer and its possible predictive relevance in future
clinical practice. The purpose of this study was to
evaluate the correlation of CD44/CD24 expression with




The protocol for this study was reviewed and approved
by the internal review board of Shin Kong Memorial
Hospital. Data were obtained from a retrospectively
maintained database consisting of patients evaluated for
gastric cancer from 1993 to 2007. Tumors were staged
according to the criteria of the American JointCommission for Cancer (AJCC 6th edition) for gastric
cancer and were classified histologically according to the
WHO criteria; Lauren’s classification was also applied
(intestinal type GC corresponds to well- or moderately
differentiated tumors; diffuse type corresponds with
poorly differentiated tumors). A retrospective review of
patients’ medical records was also completed and data
were collected for age, sex, and final pathologic
diagnosis.
During the period from January 1993 to December
2007, 500 patients received curative resection for gas-
tric cancer at the Department of Surgery of Shin-Kong
Wu Ho-Su Memorial Hospital. Among these, 95
patients (19%) developed a recurrence during long-
term follow-up.
Forty patients with gastric cancer were randomly
selected as subjects in our study. We retrospectively ana-
lyzed CD44/CD24 expression in patients’ post-operative
pathologic specimens. The patients were divided into
two groups; 20 patients with recurrent gastric cancer
were defined as the study group and the other 20
patients without recurrent gastric cancer were categor-
ized as the control group. Among patients in the non-
recurrence control group, the minimum disease-free sur-
vival was 4 years (2002–2006) and the maximum
disease-free survival was 18 years (1994–2012). A total
of 14 patients from the 20 non-recurrence group are still
living today. All included patients provided signed
informed consent to participate in the study.
Tissue preparation
Immunohistochemistry stains for CD44 and CD24 were
performed for all specimens. The cancer tissues were
fixed with formalin and embedded in paraffin. After
paraffin removal and rehydration, antigen retrieval was
performed by placing sections into a beaker containing
adequate amounts of citrate buffer (pH 6.0), then heat-
ing in pressure cooker for 10 min and cooling to room
temperature. After 10 min, 3% H2O2 was added. Pri-
mary antibody and secondary antibody (Envision Detec-
tion Kit, Wonderful Life Science Co. Ltd, Taiwan) were
added after 60 minues and 90 minutes, respectively,
coupled with PBS washing in between the addition of
antibodies. DAB substrate solution was subsequently
added and washed with running water before counter-
staining with hematoxylin. Finally, tissues were washed
with distilled water, dehydrated and mounted for micro-
scopic evaluation. The intensity (0, 1+, 2+, 3+) of tumor
cell staining was independently evaluated by two
pathologists, and discrepant results were resolved by
reviewing the cases together and agreeing on the scores.
A complete negative staining was scored as negative
(0). A weak staining (1+) was defined as minimal, but
unequivocal staining in less than 10% of tumor cell.
Figure 1 Immunohistochemical staining of C44/CD24 protein expression in recurrent gastric cancer tissue (400x). A: CD44 2+, B: CD24 -,
C: CD44 -, D: CD24 3+.
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erately/strongly positive (2+/3+) (Figure 1). Tumors
with weak and moderate/strong staining were defined
as having positive expression, while those with negative
staining only were defined as negative expression.Statistical analysis
Data were presented as mean± SD for continuous vari-
ables, and frequencies with percentages for categorical
variables. Differences between the study group (recur-
rence) and the control group (non-recurrence) were ana-
lyzed using independent t-test test for continuous
variables, and Chi-square test or Fisher’s exact test for
categorical variables as appropriate. To investigate the
association of CD44 and CD24 expression as well as
other risk factors with gastric cancer recurrence, the
point estimates and 95% confidence intervals (CIs) of
odds ratios (ORs) were calculated by univariate and
multivariate logistic regression models. Multivariate lo-
gistic regression with backward selection was applied,
wherein variables that did not improve the model fit at
P<0.05 were discarded; however, CD44 and CD24 ex-
pression as well as age were always forced into the
model. Two multivariate models were applied to evaluate
the association of CD44 and CD24 expression with gas-
tric cancer recurrence: Model 1 considered CD44 and
CD 24 as two variables, while Model 2 considered the
combined CD44/CD24 expression as one variable. All
statistical analyses were performed with SAS software
version 9.2 (SAS Institute Inc., Cary, NC, USA). A two-
tailed P<0.05 indicated statistical significance.Results
A total of 40 patients were enrolled in this study, includ-
ing 19 males and 21 females with mean age of
68.4 ± 11.4 years old (ranging from 44 to 88 years old).
Comparison of demographic and clinical characteristics
between the study group and the control group are
shown in Table 1. Study group subjects were more likely
to be classified as higher TNM stage (III-IV) than con-
trol group subjects (80% vs. 25%, P= 0.001). In addition,
the proportion of lymph node metastasis was signifi-
cantly higher in the study group than that in the control
group (90% vs. 45%, P= 0.002). Moreover, the proportion
of patients with five or more metastatic lymph nodes
was also significantly higher in the study group than in
the control group (45% vs. 15%, P= 0.007). No signifi-
cant differences were found in other characteristics be-
tween the study group and the control group. (Table 1).
Univariate and multivariate regression analysis
The univariate and multivariate associations of CD44
and CD24 expression, as well as other risk factors with
gastric cancer recurrence, are shown in Table 2. In uni-
variate analysis, patients with CD44+ showed no differ-
ence in risk of gastric cancer recurrence compared to
those who were CD44- (OR= 1.00, 95% CI: 0.29-3.45,
P= 1.000). Compared to patients who were CD24-, those
with CD24+ had higher likelihood to have gastric cancer
recurrence but without significance (OR= 1.86, 95% CI:
0.52-6.61, P= 0.339). Compared to patients with com-
bined expression of CD44-/CD24-, the unadjusted ORs
for CD44-/CD24+, CD44+/CD24-, and CD44+/CD24+
were 4.00 (95% CI: 0.55-29.10), 1.60 (95% CI: 0.30-8.49),
Table 1 Comparison of demographic and clinical
characteristics between patients with / without gastric
cancer recurrence
Characteristics Study Group Control Group P-value
(n = 20) (n = 20)
Recurrence Non-recurrence
Gender, n(%)
Male 12 (60.0) 7 (35.0) 0.113†
Female 8 (40.0) 13 (65.0)
Age (years)
mean± SD 71.2 ± 10.6 65.7 ± 11.7 0.128{
Age group, n(%)
≤65 6 (30.0) 10 (50.0) 0.197†




9 (45.0) 6 (30.0) 0.327†
Poorly differentiated
(diffuse type)
11 (55.0) 14 (70.0)
Tumor location, n(%)
Upper third of stomach 5 (25.0) 10 (50.0) 0.191}
Middle third of stomach 1 (5.0) 0 (0.0)
Lower third of stomach 14 (70.0) 10 (50.0)
TNM Stage, n(%)
I-IIa 4 (20.0) 15 (75.0) 0.001*†
III-IV 16 (80.0) 5 (25.0)
Lymph node metastasis, n(%)
No 2 (10.0) 11 (55.0) 0.002*†
Yes 18 (90.0) 9 (45.0)
Number of lymph node metastasis, n(%)
0 2 (10.0) 11 (55.0) 0.007*†
1-4 s 9 (45.0) 6 (30.0)
≥5 9 (45.0) 3 (15.0)
CD44 expression, n(%)
CD44- 10 (50.0) 10 (50.0) 1.000†
CD44+ 10 (50.0) 10 (50.0)
CD24 expression, n(%)
CD24- 10 (50.0) 13 (65.0) 0.337†
CD24+ 10 (50.0) 7 (35.0)
CD44 / CD24 expression, n(%)
CD44-/CD24- 5 (25.0) 8 (40.0) 0.622}
CD44-/CD24+ 5 (25.0) 2 (10.0)
CD44+/CD24- 5 (25.0) 5 (25.0)
CD44+/CD24+ 5 (25.0) 5 (25.0)
a Two control patients with TNM Stage 0 were grouped into Stage I-II.
*P<0.05.
† Chi-square test; { independent t-test; }Fisher’s exact test.
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cance was shown in the crude association of CD44/
CD24 expression with gastric cancer recurrence. Also,higher TNM stage (III-IV), lymph node metastasis and
higher numbers of metastasis lymph nodes, were all sig-
nificantly associated with gastric cancer recurrence.
In multivariate model 1, when CD44 and CD24 ex-
pression and age were forced into the model, only gen-
der (male vs. female, aOR= 39.64, 95% CI: 1.85-848.44,
P= 0.019), TNM stage (Stage III-IV vs. I-II, aOR = 9.63,
95% CI: 1.05-88.76, P= 0.046), and lymph node metasta-
sis (Yes vs. No, aOR= 20.92, 95% CI: 1.20-365.55,
P= 0.037) achieved a significance level allowing them to
be retained in the multivariate logistic regression model.
However, after adjusting for other risk factors, the asso-
ciation of CD44 expression (aOR= 0.66, 95% CI: 0.10-
4.26, P= 0.658) and CD24 expression (aOR= 0.09, 95%
CI: 0.01-1.35, P= 0.081) with gastric cancer recurrence
were still not significant.
In multivariate model 2, when combined CD44/CD24
expression and age were forced into the model, only
gender (male vs. female, aOR= 21.59, 95% CI: 1.24-
377.26, P= 0.035) and TNM stage (Stage III-IV vs. I-II,
aOR= 41.01, 95% CI: 3.62-464.91, P= 0.003) achieved a
significance level allowing them to be retained in the
multivariate logistic regression model. Compared to
patients with combined expression of CD44-/CD24-,
the adjusted ORs for CD44-/CD24+, CD44+/CD24-,
and CD44+/CD24+ were 0.60 (95% CI: 0.03-10.67), 1.61
(95% CI: 0.15-17.36), and 0.06 (95% CI: 0.002-2.31),
respectively. After adjusting for other risk factors, the
association of CD44/CD24 expression with gastric
cancer recurrence was still not significant.
Discussion
Evaluation of the correlation of CD44/CD24 expression
with recurrent gastric cancer revealed no differences in
risk of gastric cancer recurrence between CD44+
patients and CD44- patients. Although CD24+ patients
had a higher likelihood of gastric cancer recurrence than
CD24- patients, significance was not demonstrated. Our
study results suggest that these molecules do not appear
to be clinically useful for prediction of gastric carcinoma
recurrence after curative resection.
The role of CD44 and CD24 expression in gastric car-
cinoma has been explored for nearly thirty years. Nu-
merous studies have focused on the diagnostic and
prognostic significance of CD44 expression in human
tumors, especially gastric cancer. In 1982, CD44 was
identified as a surface glycoprotein and a lymphocyte
homing receptor found on lymphoid and epithelial cells
[8]; its main function on lymphocytes is mediating inter-
action with the endothelium, but its function on epithe-
lial cells is not entirely understood [9]. The CD44
proteins belong to a family of type I transmembrane gly-
coproteins that are encoded by a single, highly con-
served gene located on the short arm of chromosome 11
Table 2 Univariate and multivariate associations of CD44/CD24 expression and other risk factors with gastric cancer
recurrence
Characteristics Recurrence rate Univariate P-value Model 1† P-value Model 2{ P-value
OR (95%CI) aOR (95%CI) aOR (95%CI)
CD44 expression
CD44- 50.0% (10/20) 1.00 (reference) – 1.00 (reference) –
CD44+ 50.0% (10/20) 1.00 (0.29-3.45) 1.000 0.66 (0.10-4.26) 0.658
CD24 expression
CD24- 43.5% (10/23) 1.00 (reference) – 1.00 (reference) –
CD24+ 58.8% (10/17) 1.86 (0.52-6.61) 0.339 0.09 (0.01-1.35) 0.081
CD44 / CD24 expression
CD44-/CD24- 38.5% (5/13) 1.00 (reference) – 1.00 (reference) –
CD44-/CD24+ 71.4% (5/7) 4.00 (0.55-29.10) 0.171 0.60 (0.03-10.67) 0.731
CD44+/CD24- 50.0% (5/10) 1.60 (0.30-8.49) 0.581 1.61 (0.15-17.36) 0.695
CD44+/CD24+ 50.0% (5/10) 1.60 (0.30-8.49) 0.581 0.06 (0.002-2.31) 0.131
Gender
Male 63.2% (12/19) 2.79 (0.77-10.04) 0.117 39.64 (1.85-848.44) 0.019* 21.59 (1.24-377.26) 0.035*
Female 38.1% (8/21) 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
Age (years)
≤65 37.5% (6/16) 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
>65 58.3% (14/24) 2.33 (0.64-8.54) 0.201 7.77 (0.89-67.99) 0.064 4.07 (0.49-34.16) 0.196
Histology
Moderately differentiated (intestinal type) 60.0% (9/15) 1.91 (0.52-7.01) 0.330
Poorly differentiated (diffuse type) 44.0% (11/25) 1.00 (reference) –
Tumor location
Upper third +Middle third 37.5% (6/16) 1.00 (reference) –
Lower third 58.3% (14/24) 2.33 (0.64-8.54) 0.201
TNM Stage
I-IIa 21.1% (4/19) 1.00 (reference) – 1.00 (reference) – 1.00 (reference) –
III-IV 76.2% (16/21) 12.0 (2.70-53.3) 0.001* 9.63 (1.05-88.76) 0.046* 41.01 (3.62-464.91) 0.003*
Lymph node metastasis
No 15.4% (2/13) 1.00 (reference) – 1.00 (reference) –
Yes 66.7% (18/27) 11.0 (2.00-60.5) 0.006* 20.92 (1.20-365.55) 0.037*
Number of lymph node metastasis
0 15.4% (2/13) 1.00 (reference) –
1-4 s 60.0% (9/15) 8.25 (1.33-51.2) 0.024*
≥5 75.0% (9/12) 16.5 (2.25-121.2) 0.006*
† In multivariate Model 1, CD44 and CD24 expression were considered as two variables.
{ In multivariate Model 2, CD44 and CD24 expression were combined as one variable to show different combinations.
a Two control patients with TNM Stage 0 were grouped into Stage I-II.
Note: OR, odds ratio; aOR, adjusted odds ratio.
*P<0.05.
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Mr CD44 (80–90 x 10
3) is expressed in lymphoid tissue
and high Mr CD44 (130–160 x 103) is expressed in
tumor cells and keratinocytes [10]. Some aggressive
tumors are reported to be associated with the expression
of CD44. Overexpression of CD44, defined by apparently
increased expression of CD44 protein, has been linked
to poor prognosis with tumor progression and meta-
static potential in several human malignancies, includinggastric cancer [7], colorectal cancer, breast cancer [5,6],
uterine cancer, ovarian cancer, bladder cancer, lung can-
cer, hematopoietic malignancies, and gliomas [11]. A
retrospective study of 100 patients with gastric cancer
evaluated the expression of CD44 and its prognostic im-
portance, concluding that this cell adhesion molecule is
highly expressed in gastric adenocarcinoma [7]. In that
study, expression of CD44 correlated with a poor prog-
nosis in patients with the intestinal type of gastric
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CD44 could be utilized as a prognostic marker for this
group of patients. In this study, the proportion of lymph
node metastasis was significantly higher in the GC study
group than that in the control group and the proportion
of patients with 5 or more metastatic lymph nodes was
also significantly higher in the study group than in the
control group. However, while CD44 was definitely
linked with GC in our study and prognostic to some de-
gree, we could not verify its predictive capability in
terms of GC recurrence after tumor resection.
CD24, a mucin-type GPI-linked cell surface molecule
on human neutrophils and pre-B lymphocytes, plays an
important role in the margination and adhesion of cells
under shear force of blood flow [11]. Positive CD24 ex-
pression is found to occur in a subset of GC and to correl-
ate with lymphatic invasion, blood vessel invasion and
poor survival. The clinicopathological significance of
CD24 expression in human gastric adenocarcinoma was
evaluated by Chou and colleagues, who concluded that
cytoplasmic expression of CD24 was associated with inva-
siveness and poorer prognosis and can serve as a novel
target for prognostic prediction and adjuvant treatment of
patients with diffuse-type gastric adenocarcinoma after
tumor resection [12]. Further studies are needed to inves-
tigate other combinations of adhesion molecules.
In the present study, CD44 and CD24 expression, in-
dependently and in combination, were not associated
with GC recurrence. Carcinoma of the intestinal type
are more frequently CD44s and CD44v6 positive than
carcinomas of the diffuse type, and the importance of
subclassifying tumor types in investigations of CD44 in
human cancer has been demonstrated [13]. When cyto-
plasmic CD24 expression was studied in diffuse-type
gastric adenocarcinoma, it was shown to be associated
with invasiveness, lymph node metastasis and poorer
prognosis, but not specifically associated with recurrence
after tumor resection; however, no significant differences
were seen in tumor stage or lymph node metastasis be-
tween mixed-type GC with or without CD24 expression
[12]. Although there is no ideal cross-comparison be-
tween different histological grading systems, we did clas-
sify GC according to the WHO histological classification
and Lauren’s classification in the present study. We had
no cases of lymphoepithelial-like carcinoma or mucosa-
associated lymphoid tissue (MALT) lymphoma.
Another possible explanation of lack of significant
associations between CD44 and CD24 and recurrence
may be the particular isoform of CD44 identified in our
study. Up to seven molecular forms have varying func-
tional roles in vivo such as having different abilities to
bind hyaluronate, while their most important common
feature is their expression on tumor cells and correlation
with metastases [10]. These forms can be identifiedmore readily by sequencing mRNAs and only a few are
identified by protein analysis. The distribution of CD44
and CD24 may also differ and cellular sites in normal
tissue have only been identified in animal models, and
are not confirmed in normal human tissue. However,
larger forms are found as minor components in normal
tissue and low Mr forms are associated with lymphoid
cell types in tissue [14]. The function of CD44/CD24 is
complex and changes in CD44, in particular, have been
noted in carcinogenesis, including gene expression
modulation, splicing of RNA and altered glycosylation
[13]. Any of the above factors may account for the ap-
parent lack of association with recurrence in our study.
Clearly, more research is needed.
Molecular pathways involved in GC have been identi-
fied over the past twenty years [15]. Current investiga-
tions of molecular markers for gastric progenitor cells
and gastric stem cells may hold promise for learning
more about GC, its progression and propensity for re-
currence, and eventually for treatment applications. This
possibility is primarily because gastric tissue, as well as
intestinal tissue undergoes constant epithelial cell re-
placement and because stem cells and progenitor cells
play important roles in the renewal of gastric glands and
in epithelial repair following tissue injury [16]. Zhang
et al. [17] examined CD44 and CD24 in gastric cells
lines, AGS and gastric cancer tissues and identified the
tumorigenic properties, self-renewal and differentiated
progeny in CD44 +CD24+ and CD44-CD24- cell popu-
lations. As few as 200 of the positive combination of
cells injected into mice generated tumors in 50%, while
many thousands more negative combined cells were
needed to form a tumor in a second group of mice, sug-
gesting that the subpopulation of CD44 +CD24+ gastric
cell lines (AGS tumor cell lines) is GC stem cells [17]. In
protein studies, CD24, which is associated with tumor
metastasis, and Galectin-1 expression, which is asso-
ciated with immune response and tumor progression,
were studied in GC patients, giving particular attention
to staining intensity and clinicopathologic variables; the
researchers concluded that these proteins were inde-
pendent prognostic indicators of poor survival (though
not specifically associated with recurrence) and could be
useful as therapeutic targets [18]. Since we are not yet
studying the unique progenitor and stem cell popula-
tions in human models, we should continue exploring
tumor-specific protein expression that may be associated
with GC and recurrent GC, seeking to find a molecular
basis for this globally prevalent disease and new paths to
diagnosis, prognosis and treatment.
Limitations
This study has several limitations, with the main limita-
tion being its retrospective nature and limited sample
Yong et al. BMC Gastroenterology 2012, 12:95 Page 7 of 7
http://www.biomedcentral.com/1471-230X/12/95size. In addition, the functional significance of CD44
+/CD24- cells is still unclear. Their importance in me-
tastasis, and thus in disease recurrence and gastric can-
cer mortality, is not yet well understood. This small
retrospective series served as an initial study to investi-
gate the potential association between CD44 and CD24
and gastric cancer recurrence, but a study with a larger
sample is needed to confirm our preliminary results. We
must also acknowledge that we were unable to confirm
intratumor heterogeneity because there were only lim-
ited numbers of surgically resected specimens of the re-
current or metastatic tumors for repeat CD44/CD24
staining, which may be considered in future studies.
Conclusion
In conclusion, neither individual expression of CD24
and CD44 nor combined expression of CD44/CD24 was
associated with recurrence of gastric carcinoma. Since
adhesion molecules CD44 and CD24 do not appear to
be clinically useful for prediction of gastric carcinoma
recurrence after curative resection, future research is
warranted to both confirm these results and to investi-
gate other possible biomarkers.
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